In short
AZD6793 is an investigational chemical substance developed by AstraZeneca AB, currently studied as a film-coated tablet taken by mouth. It is being tested in a Phase 2 clinical trial in adults with moderate to very severe chronic obstructive pulmonary disease (COPD). The trial, authorised in the EU, plans to enrol 970 participants and will measure how AZD6793 affects the annual rate of moderate or severe COPD exacerbations compared with placebo.
Key points
- AZD6793 is an investigational substance with no marketing authorisation, developed by AstraZeneca AB.
- It is being studied in a Phase 2 trial in moderate to very severe chronic obstructive pulmonary disease (COPD).
- The trial plans to enrol 970 participants and is currently authorised in the EU.
- The medicine is given as a film-coated tablet for oral use.
- The main measure is the annualised rate of moderate or severe COPD exacerbations compared with placebo.
- The trial is registered in the EU Clinical Trials Information System as 2025-520473-40-00.
What is AZD6793?
AZD6793 is an investigational substance, meaning it has not yet received a marketing authorisation and is not available as a prescribed medicine. It is a chemically synthesised substance, classified as a small-molecule chemical compound. The product records in the EU Clinical Trials Information System (CTIS) list AstraZeneca AB as the authorisation holder and supplier of the product. The substance appears under the name AZD6793, which is both its development code and the name used in the trial records; no trade name or other name is given in the registry data. In the therapeutic area classification, AZD6793 sits within respiratory tract diseases, reflecting the condition it is being studied for.
How does AZD6793 work?
The registry data provided for this page do not state the mechanism of action of AZD6793, such as the molecular target it binds to or the biological pathway it affects. What is known from the trial record is that the substance is being tested for its effect on the rate of moderate or severe COPD exacerbations, which are episodes where breathing symptoms suddenly worsen. The specific way in which AZD6793 might influence these exacerbations is not described in the sources available here.
Which conditions is AZD6793 studied for?
- Moderate to very severe chronic obstructive pulmonary disease (COPD) — a long-term lung condition in which the airways become narrowed and damaged, causing breathing difficulty, cough and frequent chest infections. The trial studies people whose COPD is classified as moderate to very severe.
How is AZD6793 given?
AZD6793 is given as a film-coated tablet for oral use, meaning it is swallowed. The trial record lists two AZD6793 arms and one placebo arm, all oral; the dose in milligrams is not reported in the register and is therefore not stated here. The placebo is a tablet that looks the same but contains no active substance, used as a comparison.
What do the clinical trials show?
One clinical trial of AZD6793 is present in the data, registered in the EU Clinical Trials Information System under the identifier 2025-520473-40-00. It is a Phase 2, interventional study with a planned enrolment of 970 participants, and its status is authorised, meaning it has received the approvals needed to proceed. The trial compares AZD6793 with placebo in adults with moderate to very severe COPD. The primary outcome is the annualised rate of moderate or severe COPD exacerbations, which counts how many flare-ups of the disease a person has per year on average. The trial does not report a dose in milligrams, and no results are yet available in the registry record.
What side effects are known?
The sources provided for this page do not include information on side effects of AZD6793. No adverse event data are available from the trial record or from supplementary sources.